NCT02597322 - Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

June 30, 2017

Conditions

cT2a N0NxM0 Renal Tumor

Interventions

DRUG

AXITINIB

Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3 It will be supplied as 1 mg and 5 mg film coated tablets for oral administration in light protecting bottles of 60 tablets.

Trial Locations (1)

94275

Bicêtre Hospital, Le Kremlin-Bicêtre